Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. ("Zydus"), announced today that the U.S. Food and Drug Administration (USFDA) ...

The CUTX-101 NDA was initially granted Priority Review by the FDA and is supported by positive topline clinical efficacy ...

Winrevair, when added to standard of care, reduced clinical worsening events by 76% in adults recently diagnosed with PAH, trial data show.

Years of hits in sports like football and soccer, even without concussions, can trigger neuron loss and inflammation in the ...